Soren Tulstrup to Lead Shire plc's HGT's MPS Franchise

Shire plc (LSE: SHP, NASDAQ: SHPGY), today announced the appointment of Soren Tulstrup as Senior Vice President and Franchise Lead, MPS (mucopolysaccharides) for its Human Genetic Therapies (HGT) business. In this role, Soren will be responsible for developing global strategy for the MPS franchise, which includes both commercial and pipeline products, and will play a key role in strategic decisions made about the Company's growing rare disease portfolio. He will report to Sylvie Grgoire, President of Shire HGT, and will be based in Shire's office in Nyon, Switzerland.